
A young child has been brought back from the verge of death after an experimental combination of stem cell and …

It speaks to the desperation of the funding crisis for the NHS that Chief Executive of the NHS, Simon Stevens, …

GSK, under its new CEO, has made most of its waves recently not with approvals but with high-profile appointments, and …

In our latest free to attend webinar, we have joined up with NDA to bring you the latest market access …

It is easy to forget the very real dangers that CAR-T treatment present to patients after Novartis and Gilead both …

Research, published in the Journal of Women’s Health, that aimed to determine the effects of the FDA’s guidance on the …

Dear Colleague,

Access to sophisticated rapid blood tests for malaria has improved dramatically in recent years but there are still issues in …

Sanofi spent more than $1.5 billion and two decades to develop the first ever vaccine for dengue fever, only a …

Only two years ago, Valeant was so keen to get involved with a pill reported to increase the female libido …

Transparency is one of those words for which the exact meaning has become clouded by murkier connotations. The chances are …

Merck KGaA’s share price is 7% down over the course of the year – a year that, on the pharmaceutical …

Valeant has had precious little to be happy about over the last few years, it’s bounced from one piece of …

Why immunotherapies are successful in some individuals and not in others is a matter of huge importance to both patients …

It has been announced that I trial will begin in London offering the public GP consultations through their smartphone. The …